Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome

Introduction. Hemolytic uremic syndrome (HUS) is characterized by endothelial dysfunction, consumption thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. HUS generally has a dismal prognosis, except when associated with gastroenteritis caused by verotoxin-producing bacteri...

Full description

Bibliographic Details
Main Authors: R. Ramos, F. Lopes, T. Rodrigues, N. Rolim, I. Rodrigues, H. Monteiro
Format: Article
Language:English
Published: Hindawi Limited 2013-01-01
Series:Case Reports in Urology
Online Access:http://dx.doi.org/10.1155/2013/459618
id doaj-12b0a40019dd4829a83cdd42e4517d0f
record_format Article
spelling doaj-12b0a40019dd4829a83cdd42e4517d0f2020-11-24T22:38:06ZengHindawi LimitedCase Reports in Urology2090-696X2090-69782013-01-01201310.1155/2013/459618459618Advanced Prostate Cancer Presenting as Hemolytic Uremic SyndromeR. Ramos0F. Lopes1T. Rodrigues2N. Rolim3I. Rodrigues4H. Monteiro5Urology Department, Portuguese Institute of Oncology, 1099 Lisbon, PortugalUrology Department, Egas Moniz Hospital, CHLO, 1349 Lisbon, PortugalUrology Department, Egas Moniz Hospital, CHLO, 1349 Lisbon, PortugalUrology Department, Egas Moniz Hospital, CHLO, 1349 Lisbon, PortugalNephrology Department, Santa Cruz Hospital, CHLO, 2790 Carnaxide, PortugalUrology Department, Egas Moniz Hospital, CHLO, 1349 Lisbon, PortugalIntroduction. Hemolytic uremic syndrome (HUS) is characterized by endothelial dysfunction, consumption thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. HUS generally has a dismal prognosis, except when associated with gastroenteritis caused by verotoxin-producing bacteria. Cancer associated HUS is uncommon, and there are only scarce reports on prostate cancer presenting with HUS. Case Presentation. A 72-year-old man presented to the emergency department with oliguria, hematuria, and hematemesis. Clinical evaluation revealed acute renal failure, hemolysis, normal blood-clotting studies, and prostate-specific antigen value of 1000 ng/mL. The patient was started on hemodialysis, ultrafiltration with plasma exchange, and androgen blockade with bicalutamide and completely recovered from HUS. The authors review the 14 published cases on this association. Conclusion. The association of HUS and prostate cancer occurs more frequently in patients with high-grade, clinically advanced prostate cancer. When readily recognized and appropriately treated, HUS does not seem to worsen prognosis in prostate cancer patients.http://dx.doi.org/10.1155/2013/459618
collection DOAJ
language English
format Article
sources DOAJ
author R. Ramos
F. Lopes
T. Rodrigues
N. Rolim
I. Rodrigues
H. Monteiro
spellingShingle R. Ramos
F. Lopes
T. Rodrigues
N. Rolim
I. Rodrigues
H. Monteiro
Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome
Case Reports in Urology
author_facet R. Ramos
F. Lopes
T. Rodrigues
N. Rolim
I. Rodrigues
H. Monteiro
author_sort R. Ramos
title Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome
title_short Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome
title_full Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome
title_fullStr Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome
title_full_unstemmed Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome
title_sort advanced prostate cancer presenting as hemolytic uremic syndrome
publisher Hindawi Limited
series Case Reports in Urology
issn 2090-696X
2090-6978
publishDate 2013-01-01
description Introduction. Hemolytic uremic syndrome (HUS) is characterized by endothelial dysfunction, consumption thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. HUS generally has a dismal prognosis, except when associated with gastroenteritis caused by verotoxin-producing bacteria. Cancer associated HUS is uncommon, and there are only scarce reports on prostate cancer presenting with HUS. Case Presentation. A 72-year-old man presented to the emergency department with oliguria, hematuria, and hematemesis. Clinical evaluation revealed acute renal failure, hemolysis, normal blood-clotting studies, and prostate-specific antigen value of 1000 ng/mL. The patient was started on hemodialysis, ultrafiltration with plasma exchange, and androgen blockade with bicalutamide and completely recovered from HUS. The authors review the 14 published cases on this association. Conclusion. The association of HUS and prostate cancer occurs more frequently in patients with high-grade, clinically advanced prostate cancer. When readily recognized and appropriately treated, HUS does not seem to worsen prognosis in prostate cancer patients.
url http://dx.doi.org/10.1155/2013/459618
work_keys_str_mv AT rramos advancedprostatecancerpresentingashemolyticuremicsyndrome
AT flopes advancedprostatecancerpresentingashemolyticuremicsyndrome
AT trodrigues advancedprostatecancerpresentingashemolyticuremicsyndrome
AT nrolim advancedprostatecancerpresentingashemolyticuremicsyndrome
AT irodrigues advancedprostatecancerpresentingashemolyticuremicsyndrome
AT hmonteiro advancedprostatecancerpresentingashemolyticuremicsyndrome
_version_ 1725714587989311488